Company news
Kala Bio, Inc. news in 2023
Kala Bio, Inc.'s news releases, calls and decks from 2023, newest first.
KALA BIO Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 12, 2023
KALA BIO to Present at H.C. Wainwright 25th Annual Global Investment Conference
September 4, 2023
KALA BIO Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 3, 2023
Kala Pharmaceuticals Announces Name Change to KALA BIO
August 1, 2023
KALA BIO to Participate in Upcoming Investor Conferences in August
August 1, 2023
Kala Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 18, 2023
Kala Pharmaceuticals to Present at the Jefferies Healthcare Conference
June 1, 2023
Kala Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 8, 2023
Combangio, Inc., a Wholly Owned Subsidiary of Kala Pharmaceuticals, Awarded $15 Million by California Institute for Regenerative Medicine to Support Ongoing KPI-012 Program for the Treatment of PCED
April 27, 2023
Kala Pharmaceuticals Receives FDA Fast Track Designation for KPI-012, a Human MSC-S Therapy for Persistent Corneal Epithelial Defect
April 11, 2023
Kala Pharmaceuticals Appoints Dr. Francis Mah as Chief Medical Advisor
March 28, 2023
Kala Pharmaceuticals Announces Positive Safety Update from Cohort 1 of CHASE Phase 2b Clinical Trial Evaluating KPI-012 in Patients with PCED
March 26, 2023
Kala Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference
March 7, 2023
Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
March 2, 2023